Longato, Enrico
Di Camillo, Barbara
Sparacino, Giovanni
Avogaro, Angelo
Fadini, Gian Paolo
Funding for this research was provided by:
University of Padova
MIUR, Italian Ministry for Education
Italian Diabetes Society
Article History
Received: 1 June 2022
Accepted: 9 August 2022
First Online: 22 August 2022
Declarations
:
: The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. All the data used in this study were previously anonymized as per the Italian law concerning their usage for research and governance purposes. Study conduct was approved by the data owner board (Arsenà l.IT) and a formal ethics approval was deemed not necessary. Based on national regulations for retrospective studies on anonymized administrative claims, patients’ informed consent was not collected.
: Not applicable.
: AA received research grants, lecture or advisory board fees from Merck Sharp & Dome, AstraZeneca, Novartis, Boeringher-Ingelheim, Sanofi, Mediolanum, Janssen, Novo Nordisk, Lilly, Servier, and Takeda. GPF received lecture fees or grant support from Abbott, AstraZeneca, Boehringer, Lilly, Merck-Sharp-Dome, Mundipharma, Novartis, Novo Nordisk, Sanofi, Servier. EL, BDC and GS have nothing to disclose.